MAPT and Alzheimer disease: The new standards include biomarkers such as Aβ 1-42 combined with total tau or phosphorylated tau protein level in cerebrospinal fluid (CFS), amyloid PET imaging, autosomal dominant mutation (e.g., PSEN1, PSEN2, and APP mutations) in the diagnosis and identification of AD [23].